Trademark: 79350059
Word
BEXIGNUS
Status
Pending
Status Code
686
Status Date
Tuesday, February 13, 2024
Serial Number
79350059
Mark Type
4000
Filing Date
Friday, August 12, 2022
Published for Opposition
Tuesday, February 13, 2024

Trademark Owner History
Faron Pharmaceuticals Oy - Owner At Publication

Classifications
5 Pharmaceuticals used for the prevention and treatment of cancer, bone marrow dysfunction or suppressions, hematological malignancies, immunosystem related diseases and disorders, and diseases of chronic infections in human tissue of an individual; Medical preparations, namely, preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders; Sanitary preparations for medical purposes; Pharmaceutical preparations and substances for the treatment of cancer; Tumor suppressing agents; Antineoplastics being preparations and pharmaceutical products for preventing and treating cancer and other immunosystem related diseases and disorders; Anti-cancer preparations; Compounds for treating cancer, namely, pharmaceutical products for the prevention and treatment of cancer; Antibodies for medical use to prevent and treat inflammation and cancer growth and spread, bone marrow dysfunction or suppressions, hematological malignancies, and immunosystem related diseases and disorders; Biological preparations used for immune activation in the prevention and treatment of cancer, immunosystem related diseases and disorders, bone marrow dysfunction or suppressions, hematological malignancies, and chronic infections in human tissue of an individual; Adjuvants for medical purposes; Vaccine adjuvants; Anti-neoplastic preparations of chemical origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Anti-neoplastic preparations of microbial origin being pharmaceutical preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Antigens, namely, tumour antigens for medical diagnostic purposes and for anti-cancer preparations; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical use, namely, biological preparations for the treatment of conditions with poor production of hematopoietic stem cells; Biotechnological preparations for medical use, namely, biological preparations for the prevention and treatment of cancer, hematological malignancies, bone marrow dysfunction or suppressions, immunosystem related diseases and disorders, and chronic infections; Immunomodulators, namely, pharmaceutical preparations for restoring and modifying the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations for the prevention of disorders of the immune system; Serotherapeutic medicines, namely, pharmaceutical preparations used for immune activation in the treatment of cancer and in the treatment of diseases of chronic infections in human tissue of an individual; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for use in hematology

Trademark Events
Mar 11, 2024
Notification Of Possible Opposition - Processed By Ib
Feb 21, 2024
Notification Of Possible Opposition Sent To Ib
Feb 21, 2024
Notification Of Possible Opposition Created, To Be Sent To Ib
Feb 14, 2024
Notification Processed By Ib
Feb 13, 2024
Official Gazette Publication Confirmation E-Mailed
Feb 13, 2024
Published For Opposition
Jan 24, 2024
Notification Of Possible Opposition Sent To Ib
Jan 24, 2024
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 24, 2024
Notification Of Notice Of Publication E-Mailed
Jan 5, 2024
Approved For Pub - Principal Register
Dec 29, 2023
Teas/Email Correspondence Entered
Dec 29, 2023
Correspondence Received In Law Office
Dec 29, 2023
Teas Response To Office Action Received
Aug 1, 2023
Refusal Processed By Ib
Jul 8, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Jul 8, 2023
Refusal Processed By Mpu
Jun 2, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Jun 1, 2023
Non-Final Action Written
Jun 1, 2023
Assigned To Examiner
Sep 23, 2022
Application Filing Receipt Mailed
Sep 19, 2022
New Application Office Supplied Data Entered
Sep 16, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24